Investigating key epigenetic factors in breast cancer patients
"Investigating The Role of Key Non-coding RNA(s) in Breast Cancer Patients and Their Possible Crosstalk With Chromatin Remodeling Machinery"
This study is trying to see if certain genetic markers in newly diagnosed breast cancer patients can help improve how doctors diagnose and treat the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06759714 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the role of epigenetic regulators, specifically non-coding RNAs, in breast cancer. It aims to measure the expression levels of UPK1A-AS1 and UNC5B-AS1 in clinical samples from newly diagnosed breast cancer patients. By analyzing these molecular markers, the study seeks to enhance the diagnosis and prognosis of breast cancer, potentially leading to new therapeutic targets. The research highlights the significance of epigenetic dysregulation in cancer and its implications for patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are Egyptian females aged 18 years and above who have been newly diagnosed with breast cancer.
Not a fit: Patients with blood diseases, other cancers, liver cirrhosis, or evidence of distant metastases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for breast cancer patients.
How similar studies have performed: While this study explores a novel approach, previous research has indicated the potential of epigenetic markers in cancer diagnosis and prognosis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Egyptian females breast cancer patients aged 18 years and above, newly diagnosed with breast cancer. Exclusion Criteria: Blood diseases, any cancer other than breast cancer, liver cirrhosis and uterine and urinary bladder diseases or breast cancer patients with any evidence of distant metastases.
Where this trial is running
Cairo
- Faculty of pharmacy, Ain Shams University — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Sherihan Galal, phD — Ain Shams University
- Study coordinator: Sherihan Galal, phD
- Email: Dr.sherehan@pharma.asu.edu.eg
- Phone: 01022850699
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.